Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Amsterdam UMC, location VUmc
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05217758CT.gov RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Trauma | — | Completed | — | — | — |
NCT00637494CT.gov A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features | — | Terminated | — | — | — |
NCT00128505CT.gov An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression | — | Completed | — | — | — |
NCT00208156CT.gov A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression | — | Completed | — | — | — |
NCT00146523CT.gov An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression | — | Completed | — | — | — |
NCT00128479CT.gov A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression | — | Completed | — | — | — |
NCT00130676CT.gov A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression | — | Completed | — | — | — |
NCT00725270CT.gov Treatment of Schizoaffective Disorder Using Mifepristone | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mifepristone (this asset) | Amsterdam UMC, location VUmc | P3 | B · 63 |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| 17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL | Massachusetts General Hospital | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Mifepristone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Psychotic Disorder | — | P3 | BB · 64 |
| Cushing Syndrome | — | P4 | B · 62 |
| Type 2 Diabetes Mellitus | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mifepristone in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/mifepristone-major-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →